Navigation Links
Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients

ells affected by Parkinson's disease, as well as an excellent safety profile over a wide range of CERE-120 dose levels."

About Phase 2 Trial of CERE-120 Currently Underway

A double-blind, controlled Phase 2 clinical trial is now enrolling 51 patients with advanced Parkinson's disease at nine medical centers in the United States, with two thirds of patients being enrolled in the active treatment group and one third in the control group. Patients are receiving CERE-120 via stereotactic neurosurgery to deliver the drug into the putamen region of the brain. Patients will be followed for 12 months for safety and efficacy. Contacts at the medical centers involved in this study can be found through a link on the Ceregene web site: www.ceregene.com.

About CERE-120

CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and functioning normally. NTN is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease and are responsible for the major motor impairments. CERE-120 is delivered by stereotactic injection to the affected area of the brain, providing stable, long-lasting expression of NTN in a highly targeted fashion. Ceregene owns exclusive technology and product rights to CERE-120.

About Parkinson's disease

Parkinson's disease is a progressive movement disorder that affects at least one million people in the United States. It is caused by a reduction in dopamine containing nerve cells of the midbrain. Dopamine is a neurotransmitter involved in controlling movement and coordination, so Parkinson's patients experiencing a reduction of
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:5/22/2013)...  Flagship Ventures, a leading venture capital and ... today announced the appointment of Stephane ... this role, Mr. Bancel will provide strategic counsel ... addition to working closely with companies in the ... and Chief Executive Officer of Moderna Therapeutics, a ...
(Date:5/22/2013)...  Grifols, a global healthcare company based in ... study demonstrating that a higher dose of PROLASTIN © ... the alpha 1 protein in patients with alpha ... within the normal range for healthy individuals. AAT deficiency ... of the alpha 1 proteinase inhibitor (A1PI) protein ...
(Date:5/22/2013)... 2013  Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical ... unmet medical needs, today announced the appointment of ... its Board of Directors. Dr. Almenoff has extensive experience ... stage drug development. "We are delighted ... Irach Taraporewala, CEO of Ohr Pharmaceutical. "She offers tremendous ...
Breaking Medicine Technology:Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 2Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 3
... N.Y., Sept. 15 Sono-Tek Corporation (OTC Bulletin Board: ... at the symposium of advanced coating technologies, whose aim ... on coating science and technology.  The symposium was attended ... medical and energy projects and by academia from around ...
... U.S. Food and Drug Administration is notifying health care ... tablets and solution used by children and adolescents receiving ... to prevent drug overdosing of children with low body ... creatinine. The revised dosing instructions now appear in the ...
Cached Medicine Technology:Sono-Tek Presents at the 15th International Coating Science and Technology Symposium (ISCST, St. Paul, MN) 2FDA Issues New Dosing Guide for Children Using Valcyte 2
(Date:5/22/2013)... Texas (PRWEB) May 22, 2013 Beginning ... On” in the Conrad Foundation’s Spirit of Innovation ... and technical plan competition, free and open to students ... , The Spirit of Innovation Challenge celebrates the life ... to walk on the Moon. The program challenges teens ...
(Date:5/22/2013)... Rye Brook, New York (PRWEB) May 22, 2013 ... clinic that specializes in combining treatments for optimal results, ... thicken thin skin on the neck. The practice ... and seen dramatic results. , “Basically, this approach is ... neck lift,” says Westchester dermatologist Dr. Michelle ...
(Date:5/22/2013)... JoVE will publish details of a ... relation to a patients age. The method is demonstrated by ... Einstein College of Medicine. Dr. Atzmon hopes that the dissemination ... genetic thermometer to assess a patients health in relation to ... publication will feature a technique that measures telomere length. ...
(Date:5/22/2013)... GA (PRWEB) May 22, 2013 ... agency, JD Media Surge, LLC, E-Dentists.com has launched ... The blog will feature numerous topics of interest ... treatment options and dental health. , http://www.E-Dentists.com/Blog/ ... of dental Internet marketing. In addition to addressing ...
(Date:5/22/2013)... May 2013, Paris, France: Results from a ... today question whether bivalirudin is superior to ... showing similar 30-day mortality in patients with ... undergoing percutaneous coronary intervention (PCI)., European and ... as an alternative to unfractionated heparin plus ...
Breaking Medicine News(10 mins):Health News:Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date 2Health News:Westchester Dermatologist Abadir Associates Offers New Neck Lift Surgery Alternative 2Health News:How healthy are you for your age? 2Health News:Dental SEO Blog Launched by E-Dentists.com in Partnership with JD Media Surge, LLC 2Health News:Registry questions superiority of bivalirudin over heparin 2
... the perfect night,s sleepDALLAS, April 7 ... a free-standing, patent pending kiosk that contains all of the ... product breaks the mold for the industry standards of soft, ... an individual,s sleep preference of side, back or stomach sleeper. ...
... strategic analysis of technologies. , ... Atlanta, GA ... global leader in legal consulting, technology and outsourcing, today announced it ... vendor of software tools that enable rapid comprehension and decision making ...
... of anti-aging injections continue, as do false claims and risk ... ... Physicians Coalition for Injectable Safety , There is no debating ... themselves, particularly in appearance enhancing treatments that restore youth and erase ...
... traits of wisdom appear to follow a universal path ... -- Wisdom appears to be more than a subjective ... circuits and pathways, suggest U.S. researchers who compiled the ... this type of research could potentially lead to interventions ...
... therapy, household changes added 3.5 years on average, study ... home-based program for seniors that includes occupational and physical ... help people live longer, new research found. , In ... 3.5 years of lifespan compared to those who didn,t, ...
... Community Hospice of Northeast Florida , in collaboration ... across the country to complete their advance healthcare directives ... designation of April 16, 2009 ... recent gains in public awareness of the need for ...
Cached Medicine News:Health News:Now Available Online, The Pillow Bar is the Right Mix of Luxury and Necessity 2Health News:UnitedLex Announces Strategic Alliance with Oval Ideas to Enable Superior Patent Analytics 2Health News:Physicians Coalition for Injectable Safety Says There are No Substitutes for Cosmetic Injections, Offers Solutions 2Health News:Physicians Coalition for Injectable Safety Says There are No Substitutes for Cosmetic Injections, Offers Solutions 3Health News:Physicians Coalition for Injectable Safety Says There are No Substitutes for Cosmetic Injections, Offers Solutions 4Health News:Pathway to Wisdom May Be Found in Brain Circuitry 2Health News:Home-Based Program Extends Seniors' Lives 2Health News:Home-Based Program Extends Seniors' Lives 3Health News:Community Hospice Supports National Healthcare Decisions Day 2Health News:Community Hospice Supports National Healthcare Decisions Day 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: